Skip to main content

Gayathri R. Devi, PhD

Associate Director, Research Education
Associate Professor in Surgery
Associate Professor in Pathology
Office: 477 Med.Sci.Res.Bldg. (Msrb1), 2606 DUMC, Durham, NC 27710
Campus Mail: DUMC Box 2606 Med Ctr, Durham, NC 27710

Dr. Devi’s research interests include functional genomics, anti-cancer drug discovery and development, mechanisms of cancer cell signaling, tumor immunity and applications thereof for overcoming therapeutic resistance in cancer.

The lab has established prostate, inflammatory breast cancer and ovarian cellular and tumor models.

Education and Training

  • Ph.D., University of Nebraska College of Medicine, 1998

Publications

Betof, Allison S., Christopher D. Lascola, Douglas Weitzel, Chelsea Landon, Peter M. Scarbrough, Gayathri R. Devi, Gregory Palmer, Lee W. Jones, and Mark W. Dewhirst. “Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise..” J Natl Cancer Inst 107, no. 5 (May 2015). https://doi.org/10.1093/jnci/djv040.

Full Text

Devi, G. R., J. L. Allensworth, M. Evans, N. Ueno, D. McDonnell, F. Bertucci, and S. Van Laere. “80 Determination of an oxidative stress gene signature in inflammatory breast cancer patient tumors and development of a novel redox modulatory strategy in overcoming chemotherapy resistance and mediating anti-tumor efficacy.” In European Journal of Cancer, 50:31–31. Elsevier BV, 2014. https://doi.org/10.1016/s0959-8049(14)70206-0.

Full Text

Sauer, Scott Jeffrey, John B. Davis, H Kim Lyerly, Imran Shah, Kevin P. Williams, and Gayathri R. Devi. “Bisphenol a Interacts with Gper, Activates EGFR and ERK Signaling and Antagonizes Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Breast Cancer Cells.” Endocrine Reviews 35, no. 3 (June 1, 2014).

Scholars@Duke

Evans, Myron K., Artak Tovmasyan, Ines Batinic-Haberle, and Gayathri R. Devi. “Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death..” Free Radic Biol Med 68 (March 2014): 302–14. https://doi.org/10.1016/j.freeradbiomed.2013.11.031.

Full Text

Morse, Michael A., Donna Niedzwiecki, John L. Marshall, Christopher Garrett, David Z. Chang, Mebea Aklilu, Todd S. Crocenzi, et al. “A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer..” Ann Surg 258, no. 6 (December 2013): 879–86. https://doi.org/10.1097/SLA.0b013e318292919e.

Full Text

Williams, Kevin P., Jennifer L. Allensworth, Shalonda M. Ingram, Ginger R. Smith, Amy J. Aldrich, Jonathan Z. Sexton, and Gayathri R. Devi. “Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization..” Cancer Lett 337, no. 1 (August 28, 2013): 77–89. https://doi.org/10.1016/j.canlet.2013.05.017.

Full Text

Morse, Michael A., Arvind Chaudhry, Elizabeth S. Gabitzsch, Amy C. Hobeika, Takuya Osada, Timothy M. Clay, Andrea Amalfitano, et al. “Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients..” Cancer Immunol Immunother 62, no. 8 (August 2013): 1293–1301. https://doi.org/10.1007/s00262-013-1400-3.

Full Text

Devi, Gayathri R., Jennifer L. Allensworth, Shalonda M. Ingram, Ginger R. Smith, Amy J. Aldrich, and Kevin P. Williams. “Abstract 951: Cross-resistance and re-sensitization to multiple drugs in an IBC model of lapatinib acquired resistance parallels redox adaptation..” In Experimental and Molecular Therapeutics. American Association for Cancer Research, 2013. https://doi.org/10.1158/1538-7445.am2013-951.

Full Text

Nair, Smita, Amy J. Aldrich, Eoin McDonnell, Qing Cheng, Anshu Aggarwal, Pujan Patel, Monique M. Williams, et al. “Immunologic targeting of FOXP3 in inflammatory breast cancer cells..” Plos One 8, no. 1 (2013). https://doi.org/10.1371/journal.pone.0053150.

Full Text

Pages